Latest Conference Articles

Thomas LeBlanc, MD, of the Duke Cancer Institute, addresses the importance of adding a palliative care specialist to the cancer care team.

Since patients who receive CAR T-cell therapy experience unique adverse events, there will need to be education for providers who care for these patients, explained Stephen Schuster, MD, of the Perelman School of Medicine.

The high cost of new, innovative cancer treatments coming to market makes these therapies inaccessible to a lot of patients, said Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation.

William Cliby, MD, consultant, division of gynecologic surgery, department of obstetrics & gynecology, Mayo Clinic, discusses patient factors that predispose them to adverse complications during surgery for ovarian cancer and using those predictors to improve care.

Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses evolving care bundle payments to better accommodate cancer patients.

If we don't close the gap in gender differences in HPV vaccination, we will likely see an increase in HPV-related cancers, explained Anna Beavis, MD, MPH, a gynecologic oncologist fellow at Johns Hopkins University.

How are large employers adapting to, and benefiting from, the value-based care practices that are a payer demand and a provider imperative? This was the focus of a panel moderated by Bo Gamble, director of Strategic Practice Initiatives, Community Oncology Alliance (COA), during the 2018 Community Oncology Conference hosted by COA, April 12-13 in National Harbor, Maryland.

In order to make Medicare drug price negotiation a reality, the government has to have additional leverage to negotiate that it doesn't have, explained Ed F. Haislmaier, the Preston A. Wells Jr senior research fellow at the Institute for Family Community, and Opportunity at The Heritage Foundation.

Providing financial navigators in cancer centers and hospitals can have demonstrable benefits for both patients and hospitals, explained Todd Yezefski, MD, senior fellow in the Clinical Research Division at the Fred Hutchinson Cancer Research Center and Division of Medical Oncology at the University of Washington.

Our division at Stanford is very interested in investigating innovative therapies and has a particular focus on immunotherapies, explained Oliver Dorigo, MD, PhD, associate professor, obstetrics and gynecology, Stanford University Medical Center.

Ray Page, DO, PhD, president and director of research at The Center for Cancer and Blood Disorders and chair-elect of the American Society of Clinical Oncology’s (ASCO) Clinical Practice Committee, provides a look at legislation to improve patient access to treatments and address drug pricing in cancer care.

There is currently a lack of transparency with pharmacy benefit managers around drug prices and where the rebates for drugs are going, but Congress is pushing for greater transparency that will benefit patients, said Ted Okon, executive director of the Community Oncology Alliance.

How are community practices coping with administering chimeric antigen receptor (CAR)-T treatments? At the 2018 Community Oncology Conference hosted by the Community Oncology Alliance, Houston Holmes, MD, MBA, FACP, Texas Oncology, shared his experience with administering CAR T-cells in a community cancer center–based setting.

Stacey McCullough, PharmD, senior vice president of pharmacy at Tennessee Oncology, discusses the importance of the pharmacist there are more advances being made and therapeutic options becoming available in oncology.

The Merit-based Incentive Payment System (MIPS) is a big program designed to be applied to all clinicians, which makes it complex to figure out how to do right, explained Richard Kane, senior director at Avalere.

Typically, cancer pain management is carved out of policies that try to restrict opioid prescribing in an effort to combat the opioid epidemic, but with more and more patients surviving their cancer, there is some uncertainty regarding who is affected by these policies, explained Bob Twillman, PhD, executive director for the Academy of Integrative Pain Management.

Richard Kane and Caroline Pearson, both from Avalere Health, provided oncologists gathered at the 2018 Community Oncology Conference an overview of reimbursement programs offered by CMS and advice on navigating them.

At the 2018 Community Oncology Conference hosted by the Community Oncology Alliance, April 12-13 in National Harbor, Maryland, FDA Commissioner Scott Gottlieb, MD, provided the audience with an overview of current and future plans of the regulatory agency, particularly its strides within the molecular diagnostic testing space.

The more data providers have on a patient, the better understanding they have about the type of treatment plan that works best with the patient’s goals, explained Torrie K. Fields, MPH, senior program manager of Palliative Care Program Design & Implementation for Blue Shield of California.

Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center, discusses the current standard of treatment for patients with advanced endometrial cancer as well as the role novel therapies, such as targeted therapies and immunotherapy, play in the treatment of the disease.

In the last few years, there’s been a real surge in interest in professional satisfaction in healthcare, according to Mark Friedberg, MD, MPP, senior natural scientist and director of the Boston office at RAND Corporation.

Getting to value in healthcare has proven to be difficult, but succesful programs have certain characteristics, said David Blumenthal, MD, MPP, president of The Commonwealth Fund.

Barbara Balik, EdD, MS, RN, co-founder of Aefina Partners and senior faculty at the Institute of Healthcare Improvement, recognizes the positives and negatives of electronic health records.

While clinicians can have a bad reaction to the idea of “cookbook medicine,” it can really result in patients getting the best treatment, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.

M. Kristina Wharton, MPH, of the Department of Global Health Management and Policy at Tulane University School of Public Health and Tropical Medicine, talks about the services federally qualified centers provide, specifically how they help patients access medications.

Shantanu Agrawal, MD, MPhil, CEO and president of National Quality Forum, recognizes the importance of diminishing health disparities.

While there has been progress with using chimeric antigen receptor (CAR) T cells to treat multiple myeloma, these treatments aren’t ready for prime time, said Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.

Tom Gallo, president of the Association of Community Cancer Centers, discusses how burnout is on the rise, but being better addressed now, as well as how technology can both contribute to and alleviate burnout.